Nektar Therapeutics (NKTR) Operating Income (2016 - 2025)
Historic Operating Income for Nektar Therapeutics (NKTR) over the last 16 years, with Q3 2025 value amounting to -$31.7 million.
- Nektar Therapeutics' Operating Income rose 778.28% to -$31.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$98.1 million, marking a year-over-year increase of 3591.34%. This contributed to the annual value of -$105.2 million for FY2024, which is 6010.45% up from last year.
- According to the latest figures from Q3 2025, Nektar Therapeutics' Operating Income is -$31.7 million, which was up 778.28% from -$36.2 million recorded in Q2 2025.
- In the past 5 years, Nektar Therapeutics' Operating Income registered a high of $14.3 million during Q4 2024, and its lowest value of -$152.8 million during Q2 2022.
- Over the past 5 years, Nektar Therapeutics' median Operating Income value was -$50.6 million (recorded in 2023), while the average stood at -$68.6 million.
- In the last 5 years, Nektar Therapeutics' Operating Income plummeted by 4181.76% in 2021 and then surged by 14281.58% in 2024.
- Over the past 5 years, Nektar Therapeutics' Operating Income (Quarter) stood at -$112.9 million in 2021, then surged by 53.53% to -$52.5 million in 2022, then surged by 36.13% to -$33.5 million in 2023, then soared by 142.82% to $14.3 million in 2024, then tumbled by 320.74% to -$31.7 million in 2025.
- Its Operating Income stands at -$31.7 million for Q3 2025, versus -$36.2 million for Q2 2025 and -$44.5 million for Q1 2025.